Logo

AbbVie and Eisai's Humira (adalimumab) Receives MHLW's Approval for Pyoderma Gangrenosum

Share this

AbbVie and Eisai's Humira (adalimumab) Receives MHLW's Approval for Pyoderma Gangrenosum

Shots:

  • The approval of additional indication is based on a P-lll study involve the assessing the efficacy and safety of Humira targeting the patients with active ulcers in Japan who were diagnosed with PG but were not sufficiently effective with local treatment- or who were judged to be unsuitable for local treatment
  • Result: The proportion of patients achieving at 100 (targeted PG ulcer healed) of the target PGAR @26wks. of administration (54.5%)
  • The indication marks Humira’s 12th indication in Japan and making it the world’s first drug indicated for the treatment of PG. Humira has received MHLW’s ODD for the treatment of PG in 2019

 ­ Ref: Eisai | Image: abbvie

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions